Published in final edited form as:

ACS Chem Biol. 2009 March 20; 4(3): 199–208. doi:10.1021/cb800277n.

Alpha Anomers of iGb3 and Gb3 Stimulate Cytokine Production by Natural Killer T Cells

Ning Yin[§], Xiangtian Long[§], Randal D. Goff[§], Dapeng Zhou[†], Carlos Cantu III[‡], Jochen Mattner[†], Pierre Saint Mezard[†], Luc Teyton[‡], Albert Bendelac[†], and Paul B. Savage^{§,*}

[§]Brigham Young University, Department of Chemistry and Biochemistry, Provo, UT 84602

[†]University of Chicago, Department of Pathology, Chicago, IL 60637

[‡]Scripps Research Institute, Department of Immunology, La Jolla, CA 92037

Abstract

Natural killer T cells (NKT cells) respond to presentation of specific glycolipids with release of a variety of proinflammatory and immunomodulatory cytokines. The repertoire of glycolipid antigens for these cells includes α -glycosylceramides, α -glycosyldiacylglycerols, and the triglycosylceramide iGb3. Two features of iGb3 set it apart from these other antigens: (1) three sugars are required for stimulation and (2) the glycosidic bond between ceramide and the proximal sugar is beta in iGb3 whereas it is alpha in other antigens. We have synthesized the alpha versions of iGb3 and Gb3 and demonstrate that they are effective antigens for NKT cells and that they do not require lysosomal processing to the monoglycosylceramides for stimulation. These triglycosylceramides constitute a new class of antigen that stimulates NKT cells comparably to monoglycosylceramides.

Introduction

Natural killer T cells (NKT cells) are a subpopulation of T cells that control multiple immune responses including autoimmune, antitumor, and allergic reactions.¹ In response to presentation of specific types of glycolipids, NKT cells are capable of rapidly producing a variety of cytokines that in turn trigger proinflammatory and/or immunomodulatory immune responses.^{1,2} A key step in the stimulation of NKT cells involves interactions among three molecules: (1) a T cell receptor on NKT cells, (2) a glycolipid, and (3) an antigen presentation protein, termed CD1d, found on antigen presenting cells.

Due to the impact that NKT cells have on human health, there has been considerable interest in understanding the types of glycolipids that can stimulate cytokine release from NKT cells.^{1,3} Stimulation of NKT cells has been studied extensively in the context of α -galactosylceramides first isolated from a marine sponge (e.g., **1** in Figure 1),⁴ and recently α -glycosylceramides (**2**)^{5–7} and α -glycosyldiacylglycerols (**3**)⁸ from bacterial sources⁹ have been identified as ligands for NKT cells. A feature common to these glycolipids is the alpha linkage of the sugar bonded to the lipid portion of the molecules.

Paul B. Savage, Professor and Associate Chair, Department of Chemistry and Biochemistry, Brigham Young University, C100 BNSN, Provo, UT 84602, Phone: 801-422-4020, Fax: 801-422-0153, paul_savage@byu.edu.

Supporting Information. Experimental procedures for preparation of α iGb3, and α Gb3. ¹H and ¹³C NMR spectra of α iGb3, and α Gb3. Methods of measuring cytokine production stimulated by CD1d presentation of glycolipids to NKT cells. This material is available free of charge via the Internet at <http://pubs.acs.org>.

iGb3 (Figure 2) is a triglycosylceramide that has been identified as an antigen for NKT cells,¹⁰ and controversy remains regarding its role as an endogenous ligand for NKT cells.^{11,12} Notably, Gb3 (Figure 2), an isomer of iGb3, is not an antigen for NKT cells. A feature of iGb3 that distinguishes it from other known NKT cell antigens is the linkage between ceramide and the proximal sugar. In iGb3, this linkage is beta, in contrast to the antigens in Figure 1. In addition, bacterial antigens for NKT cells are generally considered to be monoglycosylceramides and monodiacylglycerols,⁷ while iGb3 contains three sugars.

An important aspect of glycolipid presentation to NKT cells is the processing that can occur in the lysosomes of antigen presenting cells.¹ Glycolipids are trafficked to lysosomes, and within these organelles a variety of glycosidases are present that can truncate oligoglycosylceramides to monoglycosylceramides prior to presentation to NKT cells. Others^{13,14} and we^{6,7} have shown that most diglycosylceramides require lysosomal processing to monoglycosylceramides before they can cause NKT cell stimulation. However, in the case of iGb3, it is clear that all three sugars are necessary; β -lactosylceramide, the diglycosylceramide derived from iGb3 via truncation of the terminal galactose, does not stimulate NKT cells.¹⁰

While alpha and beta anomers of monoglycosylceramides have been prepared and tested for NKT cell stimulatory activity, only variants of iGb3 with beta linkages between the proximal sugar and the ceramide have been prepared and tested as NKT cell antigens.^{10,15} To determine if alpha anomers of iGb3 and related glycolipids are antigens for NKT cells, we prepared α iGb3 and α Gb3 (Figure 2). It was anticipated that these triglycosylceramides would require truncation to α -glucosylceramide in lysosomes for effective stimulation of NKT cells. In early structure activity studies of glycosylceramides with NKT cells, α -glucosylceramide was identified as an antigen for NKT cells,¹⁶ indicating that truncation of α iGb3 would yield a stimulatory antigen. Wang and coworkers,¹⁴ showed that α -lactosylceramide stimulates NKT cells and that glycosidase-mediated truncation was required for stimulation. That is, the terminal galactose had to be removed to give α -glucosylceramide for stimulation to occur.

Results and Discussion

Syntheses of Gb3 and iGb3 have been reported,^{17,18} however, α Gb3, and α iGb3 have not been reported and required a modified protecting group strategy, as compared to the syntheses of Gb3 and iGb3, to allow formation of the α -carbohydrate-ceramide bond. A key aspect in the syntheses of these glycolipids was generation of appropriately protected lactose derivatives. We found that **4**¹⁹ (Scheme 1) was appropriate for our syntheses of α Gb3 and α iGb3.

Synthesis of α iGb3 (Scheme 1) began with coupling of **4** and acetobromogalactose (**5**) followed by protection of the remaining alcohol generating **6**. Liberation of the C1 hydroxyl group gave **7** and coupling with **8** gave a mixture of anomers (predominately α). The anomers were difficult to separate at this stage, so the ester groups were removed and the anomers were separated effectively. Reductive deprotection gave α iGb3.

A closely related process was used in the synthesis of α Gb3 (Scheme 2). Selective protection of the hydroxyl group at C3' in **4** gave **10**. Coupling with **5** provided the protected Gb3 trisaccharide (**11**). The anomeric position of the reducing sugar was revealed and the trisaccharide was coupled with **8** to give **12**. Sequential deprotection yielded α Gb3.

Measurement of the abilities of glycolipids to stimulate NKT cells requires a source of CD1d, typically expressed by antigen-presenting cells, and NKT cells. Dose-response experiments with these glycolipids were performed with dendritic cells as antigen-presenting cells in an assay measuring IL-2 release by a mouse DN32.D3 NKT cell hybridoma.²⁰ As expected, results indicated that cytokine release (IL-2) is dependent on iGb3 concentration (Figure 3).

Notably, Gb3 did not stimulate, confirming that the CD1d-NKT cell recognition of glycolipids is specific for the substitution pattern offered by iGb3. In contrast, α iGb3 and α Gb3 stimulated cytokine production with this NKT cell hybridoma. To confirm that this observation was not unique to mouse NKT cells, we determined stimulatory activity of α iGb3 with a human NKT cells line and found it to be a very potent stimulator (data not shown). However, from these results it was not clear if α iGb3 and α Gb3 directly stimulated NKT cells or if they required truncation to α -glucosylceramide to become stimulatory.

Previous work demonstrated that α -galactosylceramides substituted at the C4 position on the carbohydrate with a second sugar required processing for stimulation of NKT cells.^{10,13} Both α iGb3 and α Gb3 fit this pattern of substitution; therefore, it was expected that they would require truncation. Use of antigen-presenting cells that express tail-deleted CD1d (TD-CD1d) allows observation of influences of lysosomal processing and the influence of lipid transfer proteins on NKT cell stimulation. TD-CD1d does not cycle to lysosomal compartments and is therefore not loaded with processed glycolipids.²¹ Attempts to stimulate NKT cells using TD-CD1d and iGb3, α iGb3, and α Gb3 resulted in minimal cytokine release (data not shown) indicating that protein-assisted loading and/or glycolipid processing was required for stimulation of NKT cells.

To determine the requirements for lipid transfer protein-assisted loading of CD1d, we used a gel-shift assay in which CD1d was first loaded with a charged glycolipid (trisialoganglioside GT1b).²² The complex was treated with α iGb3 or α Gb3 in the presence or absence of saposin B, a lipid transfer protein.²³ Displacement of GT1b from CD1d with either of these neutral glycolipids resulted in a decrease in electrophoretic mobility (Figure 4). Without saposin B, no displacement of GT1b was observed, but efficient loading, as indicated by the shift in gel mobility, was observed with saposin B. This result indicated that without processing (i.e., loss of carbohydrate groups), these glycolipids were bound by CD1d and that a lipid transfer protein was required for loading.

The remaining issue was whether these glycolipids, loaded into CD1d, were capable of stimulating NKT cells without truncation of the oligosaccharide. To address this issue and to avoid any participation by glycosidases, we used CD1d immobilized in plastic plates rather than antigen presenting cells in observing NKT cell stimulation.²² As with the CD1d loading experiments, NKT cell stimulation was performed in the presence and absence of saposin B. Stimulation was observed as a function of IL-2 release from NKT cells (mouse DN32.D3 hybridomas), which was in turn measured by proliferation (incorporation of radiolabeled thymidine) of an IL-2 responsive cytotoxic T cell line (CTLL). As expected, in the absence of saposin B, no stimulation was observed (Figure 5). However, in the presence of the lipid transfer protein, NKT cell stimulation was observed with both α iGb3 and α Gb3. IL-2 production stimulated by these glycolipids was compared to that from an α -galactosylceramide closely related to **1** (Figure 1). The α -galactosylceramide used contained ceramide derived from a C₁₈ phytosphingosine chain and a nervonic acid acyl chain. We have shown that α -galactosylceramides based on this ceramide are highly stimulatory antigens of NKT cells.²⁴

Tetramer staining of NKT cells by glycolipid-loaded CD1d tetramers is a method commonly used to study association of glycolipids with T cell receptors on NKT cells.^{25,26} NKT cell receptors are comprised of V α 14 and V α 24 chains in mice and humans, respectively, and a limited repertoire of V β chains.¹ It has been observed that iGb3 recognition is strongest with NKT cell receptors with V β 7 chains,²⁷ while α -galactosylceramides, such as PBS57,²⁴ are recognized by NKT cell receptors with variety of V β chains (i.e., V β 8.2, 8.1, 7, and 2). Staining of NKT cells with CD1d tetramers loaded with α iGb3 and α Gb3 (Figure 6) indicated that only NKT cells with receptors with V β 8.2 chains were significantly stained by tetramers loaded with these glycolipids, demonstrating the specific recognition of these trisaccharides.

Conclusions

With the discovery of glycolipids that stimulate cytokine release by NKT cells have come efforts to determine the structural features of glycolipids required for recognition by CD1d and T cell receptors. Both the ceramide and carbohydrate portions of monoglycosylceramides have been the focus of multiple studies, and the alpha anomeric configuration of the sugar bonded to ceramide has been identified as a key structural element in providing stimulatory properties. Because iGb3 has a beta anomeric configuration at the ceramide bond, it is distinct from other stimulatory glycolipids, and the fact that closely related glycolipids, such as Gb3 (an isomer of iGb3), are not stimulatory demonstrate the specificity of the protein carbohydrate interactions. Synthesis of α iGb3 and α Gb3 has allowed observation of the effects of alterations in the anomeric configuration at the sugar-ceramide bond. In a fashion similar to iGb3, these glycolipids require lipid transfer proteins for loading into CD1d. However, it was unexpected that α iGb3 and α Gb3 would not require lysosomal processing to become stimulatory. Glycolipids from *Sphingomonas* spp. include a tetrasaccharide linked to ceramide through an α -glycosidic bond, and this glycolipid, without lysosomal processing, has been described as weakly stimulatory if the ceramide portion of the molecule is sufficiently hydrophobic.²⁸ Its recognition may be similar to that of α iGb3 and α Gb3.

Differentiation of iGb3 and Gb3 is presumably due to protein-carbohydrate interactions. Because similar differentiation is not observed with α iGb3 and α Gb3, it is likely that the terminal sugars in these glycolipids are not intimately involved in interactions with the T cell receptor and may be solvent exposed in the complex. In the crystal structure of the complex of CD1d loaded with an α -galactosylceramide bound to the T-cell receptor of an NKT cell, the receptor docked at the end of the CD1d binding cleft exposing a portion of the glycolipid to solvent.²⁹ If α iGb3 and α Gb3 interact similarly with CD1d and with the T cell receptor, it is likely that the two terminal sugars are tolerated in this solvent exposed portion of the complex.

Because α iGb3 and α Gb3 stimulate NKT cells, great care must be taken to ensure that β -glycosylceramides such as iGb3 are not contaminated with alpha anomers. The greatest danger comes from false positives, that is, misinterpreting trace contamination with a strong stimulator as weak stimulation by another glycolipid. In our earlier studies of iGb3 stimulation of NKT cells, we used iGb3 from three different sources, including glycolipid isolated from a natural source, to verify that stimulation was coming from iGb3.

As the structural requirements of exogenous and endogenous antigens for NKT cells are better understood, it will become easier to manipulate the responses of these cells. Control of NKT cell responses may lead to improved treatments to a wide range of disease states, including infection and autoimmunity. The discovery that α iGb3 and α Gb3 are antigens for NKT cells increases the number and understanding of stimulatory glycolipids.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Financial support from the National Institutes of Health (NIAID, P01 AI053725) is gratefully acknowledged. D. Z. and J. M. were supported by Cancer Research Institute (New York) Fellowship grants.

References

1. Bendelac A, Savage PB, Teyton L. Biology of NKT cells. *Annual Rev. Immunol* 2007;25:297–336. [PubMed: 17150027]

2. Matsuda JL, Mallevaey T, Scott-Browne J, Gapin L. CD1d-restricted iNKT cells, the ‘Swiss-Army knife’ of the immune system. *Curr. Op. Immunol* 2008;20:358–368.
3. Savage PB, Bendelac A, Teyton L. Glycolipids for natural killer T cells. *Chem. Soc. Rev* 2006;35:771–779. [PubMed: 16936925]
4. Natori T, Koezuka Y, Higa T. Agelasphins, novel α -galactosylceramides from the marine sponge *Agelas mauritianus*. *Tetrahedron Lett* 1993;34:5591–5592.
5. Kinjo Y, Wu D, Kim G, Xing G-W, Poles MA, Ho DD, Tsuji M, Kawahara K, Wong C-H, Kronenberg M. Recognition of bacterial glycosphingolipids by natural killer T cells. *Nature* 2005;434:520–525. [PubMed: 15791257]
6. Mattner J, DeBord KL, Goff RD, Cantu C, Zhou D, Saint-Mezard P, Wang V, Gao Y, Yin N, Hoebe K, Schneewind O, Ismail N, Walker D, Buetler B, Teyton L, Savage PB, Bendelac A. Both exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. *Nature* 2005;434:525–528. [PubMed: 15791258]
7. Long X, Deng S, Zang Z, Mattner J, Zhou D, McNary N, Goff RD, Teyton L, Bendelac A, Savage PB. Synthesis and evaluation of stimulatory properties of *Sphingomonadacea* glycolipids. *Nature Chem. Biol* 2007;3:559–564. [PubMed: 17660835]
8. Kinjo Y, Tupin E, Wu D, Fujio M, Garcia-Navarro R, Benhnia MR, Zajonc DM, Ben-Manachem G, Ainge GD, Painter GF, Khurana A, Hoebe K, Behar SM, Buetler B, Wilson IA, Tsuji M, Sellati TJ, Wong C-H, Kronenberg M. Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. *Nat. Immunol* 2006;7:978–986.
9. Kim S, Lalani S, Parekh VV, Vincent TL, Wu L, Van Kaer L. Impact of bacteria on the phenotype, functions, and therapeutic activities of invariant NKT cells in mice. *J. Clin. Invest* 2008;118:2301–2315. [PubMed: 18451996]
10. Zhou D, Mattner J, Cantu C III, Yin N, Gao Y, Sagiv Y, Hudspeth K, Wu Y, Teneberg S, Wang D, Proia R, Lavery SB, Savage PB, Teyton L, Bendelac A. Lysosomal glycosphingolipid recognition by NKT cells. *Science* 2004;306:1786–1789. [PubMed: 15539565]
11. Porubsky S, Speak AO, Luckow B, Cerundolo V, Platt FM, Grone HJ. Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency. *Proc. Natl. Acad. Sci. USA* 2007;104:5977–5982. [PubMed: 17372206]
12. Li Y, Zhou D, Xia C, Wang GP, Lavery SB. Sensitive quantitation of isoglobotriaosylceramide in the presence of isobaric components using electrospray ionization-ion trap mass spectrometry. *Glycobiology* 2008;18:166–176. [PubMed: 18048405]
13. Prigozy TI, Naidenko O, Qasba P, Elewaut D, Brossay L, Khurana A, Natori T, Koezuka Y, Kulkarni A, Kronenberg M. Glycolipid antigen processing for presentation by CD1d molecules. *Science* 2001;291:664–667. [PubMed: 11158680]
14. Zhang W, Zheng X, Xia C, Perali RS, Yao Q, Liu L, Zheng P, Wang PG. α -Lactosylceramide as a novel “sugar-capped” CD1d ligand for natural killer T cells: biased cytokine profile and therapeutic activities. *ChemBiochem* 2008;9:1423–1430. [PubMed: 18478523]
15. Chen W, Xia C, Wang J, Thapa P, Li Y, Nadas J, Zhang W, Zhou D, Wang GP. Synthesis and structure-activity relationship study of isoglobotrihexosylceramide analogues. *J. Org. Chem* 2007;72:9914–9923. [PubMed: 18020363]
16. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, Ueno H, Nakagawa R, Sato H, Kondo E, Koseki H, Tanguchi M. CD1d-restricted and TCR-mediated activation of V α 14 NKT cells by glycosylceramides. *Science* 1997;278:1626–1629. [PubMed: 9374463]
17. Qiu D, Schmidt RR. Glycosyl imidates, 52. Synthesis of globotriaosylceramide (Gb3) and isoglobotriaosylceramide (iGb3). *Liebigs Ann. Chem* 1992:217–224.
18. Nicolaou KC, Caulfield K, Kumazawa T. A practical and enantioselective synthesis of glycosphingolipids and related compounds. Total synthesis of globotriaosylceramide (Gb3). *J. Am. Chem. Soc* 1988;110:7910–7912.
19. Jansson K, Ahlfors S, Frejd T, Kihlberg J, Magnusson G. 2-(Trimethylsilyl)ethyl glycosides. 3. Synthesis, anomeric deblocking, and transformation into 1,2-trans 1-O-acyl sugars. *J. Org. Chem* 1988;53:5629–5647.
20. Park SH, Roark JH, Bendelac A. Tissue-specific recognition of mouse CD1 molecules. *J. Immunol* 1998;160:3128–3134. [PubMed: 9531267]

21. Chiu YH, Park SH, Benlagha K, Forestier C, Jayawardena-Wolf J, Savage PB, Teyton L, Bendelac A. Multiple defects in antigen presentation and T cell development by mice expressing cytoplasmic tail-truncated CD1d. *Nature Immunol* 2002;3:55–60. [PubMed: 11731798]
22. Cantu C, Benlagha K, Savage PB, Bendelac A, Teyton L. The paradox of immune molecular recognition of alpha-galactosylceramide: low affinity, low specificity for CD1d, high affinity for alpha beta TCRs. *J. Immunol* 2003;170:4673–4682. [PubMed: 12707346]
23. Zhou D, Cantu CC, Sagiv Y, Kulkarni AB, Qi X, Morales C, Grabowski GA, Benlagha K, Savage PB, Bendelac A, Teyton L. Science 2004;303:523–527. Editing of Cd1-bound lipid antigens by endosomal lipid transfer proteins. [PubMed: 14684827]
24. Liu Y, Goff RD, Zhou D, Mattner J, Sullivan BA, Khurana A, Cantu C, Altman JD, Teyton L, Bendelac A, Savage PB. A modified α -galactosyl ceramide for staining and stimulating natural killer T cells. *J. Immun. Methods* 2006;312:34–39.
25. Benlagha K, Weiss A, Beavis A, Teyton L, Bendelac A. In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers. *J. Exp. Med* 2000;191:1895–1903. [PubMed: 10839805]
26. Matusda JL, Naidenko OV, Gapin L, Nakayama T, Taniguchi M, Wang C-R, Koezuka Y, Kronenberg M. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. *J. Exp. Med* 2000;192:741–754. [PubMed: 10974039]
27. Schumann J, Mycko MP, Dellabona P, Casorati G, MacDonald HR. Cutting edge: influence of the TCR Vbeta domain on the selection of semi-invariant NKT cells by endogenous ligands. *J. Immunol* 2006;176:2064–20688. [PubMed: 16455960]
28. Kinjo Y, Pei B, Bufali S, Raju R, Richardson SK, Imamura M, Fujio M, Wu D, Khurana A, Kawahara K, Wong C-H, Howell AR, Seeberger PH, Kronenberg M. Natural *Sphingomonas* glycolipids vary greatly in their ability to activate natural killer T cells. *Chemistry & Biology* 2008;15:654–664. [PubMed: 18635002]
29. Borg NA, Wun KS, Kjer-Nielsen L, Wilce MCJ, Pellicci DG, Koh R, Besra G, Bharadwaj M, Godfrey DI, McCluskey J, Rossjohn J. CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. *Nature* 2007;448:44–49. [PubMed: 17581592]

Figure 1.
Naturally occurring glycolipids that stimulate cytokine release from NKT cells.

Figure 2.
Structures of triglycosylceramides used in the present study.

Figure 3.
Dose response (IL-2 production) of NKT cells (mouse hybridoma DN32.D3) to glycolipids:
○ iGb3, ● α iGb3, Δ Gb3, $\blacktriangle$ $\alpha\Delta$ Gb3.

Figure 4.

Gel-shift assays of GT1b displacement by α iGb3 and α Gb3. CD1d-GT1b complex- 2 μ M, glycolipids-26 μ M, saposin B- 2 μ M.

Figure 5. IL-2 release in the culture supernatant determined via tritiated thymidine incorporation by the IL-2 indicator cell line CTLL-2: ■: absence of saposin B. □: presence of saposin B.

Figure 6.

NKT cell hybridomas (DN32.D3) expressing different V β chains in their T cell receptors were stained by CD1d tetramers loaded with the indicated glycolipids. The control used was α -galactosylcholesterol.

Scheme 1.
 Synthesis of αiGb3 (yields in parentheses).

Scheme 2.
Synthesis of αGb3 .